Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors.

A fragment-based design and synthesis of three novel series of aminopyridone-linked benzimidazoles as potential anticancer candidates with significant CDK9 inhibition was implemented. All synthesized compounds were submitted to National Cancer Institute, 60 cell lines and seven-dose cytotoxicity toward three cancer cells. Compounds , , , , and exhibited significant cytotoxicity and selectivity with IC range of 7.